MedPath

Probiotics in the Treatment of Irritable Bowel Syndrome

Not Applicable
Conditions
Irritable Bowel Syndrome
Interventions
Dietary Supplement: Mutaflor
Other: Pasteurized sauerkraut
Other: Raw, lacto-fermented sauerkraut
Other: Placebo capsule
Registration Number
NCT02953171
Lead Sponsor
University of Copenhagen
Brief Summary

The aim of the present study is to assess the efficacy of two different probiotic products, lacto-fermented sauerkraut and the supplement Mutaflor, in the treatment of irritable bowel syndrome.

Detailed Description

Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder that affects around 11% of the population globally. Several factors have been implicated in the pathogenesis of IBS, including psychological stress, gastrointestinal motility, and diet. More recently, it has become clear that the gastrointestinal microbiota may play a critical role in the pathophysiology of this functional GI condition.

Gut microbiome manipulation, for example through the use of probiotic and prebiotic supplements, has shown some promise in the treatment of IBS. However, the research in this area is still in its infancy, and it remains unclear what type of intervention that is the preferred choice in cases of IBS. Many, if not most, probiotic supplements on the market today contain bacteria that are incapable of colonizing the human gut, which may partly explain why the health effects associated with the use of probiotics tend to be temporary, rather than permanent.

Several studies have investigated how the use of probiotic supplements containing Bifidobacteria and Lactobacilli affect the clinical outcome of patients with IBS. However, to date, no studies have assessed whether fermented vegetables, a "natural" source of probiotic bacteria, are useful in the treatment of IBS. Moreover, little is known about how other types of probiotic bacteria, such as those belonging to the genus Escherichia, affect symptoms of IBS.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
140
Inclusion Criteria

Rome III criteria (Criteria fulfilled for the last 6 months with symptom onset at least 3 months prior to diagnosis):

Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months associated with two or more of the following:

  1. Improvement with defecation
  2. Onset associated with a change in frequency of stool
  3. Onset associated with a change in form (appearance) of stool
Exclusion Criteria
  • Psychiatric disorder
  • Metabolic disease
  • Chronic infection
  • Organic gastrointestinal disorder
  • Pregnancy
  • Breastfeeding

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Pasteurized sauerkraut+Placebo capsulePlacebo capsule75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
Pasteurized sauerkraut+Probiotic capsuleMutaflor75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
Pasteurized sauerkraut+Placebo capsulePasteurized sauerkraut75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
Raw sauerkraut+placebo capsuleRaw, lacto-fermented sauerkraut75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
Pasteurized sauerkraut+Probiotic capsulePasteurized sauerkraut75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
Raw sauerkraut+Probiotic capsuleRaw, lacto-fermented sauerkraut75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
Raw sauerkraut+placebo capsulePlacebo capsule75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
Raw sauerkraut+Probiotic capsuleMutaflor75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
Primary Outcome Measures
NameTimeMethod
IBS Symptom Severity Scale (IBS-SSS).Change from day 0 to day 42
Secondary Outcome Measures
NameTimeMethod
The Quality of Life Scale (QOLS)Change from day 0 to day 42
Fecal microbiome diversityChange from day 0 to day 42

16S rRNA gene sequences (prokaryotes)

Body weightChange from day 0 to day 42

Trial Locations

Locations (1)

Volvat Medisinske Senter, Majorstuen

🇳🇴

Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath